BR112021022404A2 - Composições de oximetazolina e métodos para tratamento de distúrbios oculares - Google Patents

Composições de oximetazolina e métodos para tratamento de distúrbios oculares

Info

Publication number
BR112021022404A2
BR112021022404A2 BR112021022404A BR112021022404A BR112021022404A2 BR 112021022404 A2 BR112021022404 A2 BR 112021022404A2 BR 112021022404 A BR112021022404 A BR 112021022404A BR 112021022404 A BR112021022404 A BR 112021022404A BR 112021022404 A2 BR112021022404 A2 BR 112021022404A2
Authority
BR
Brazil
Prior art keywords
oxymetazoline
compositions
methods
eye disorders
treating eye
Prior art date
Application number
BR112021022404A
Other languages
English (en)
Inventor
David Jacobs
Tina Devries
Original Assignee
Rvl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rvl Pharmaceuticals Inc filed Critical Rvl Pharmaceuticals Inc
Publication of BR112021022404A2 publication Critical patent/BR112021022404A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições de oximetazolina e métodos para tratamento de distúrbios oculares. a presente revelação é direcionada a composições que compreendem oximetazolina e métodos de estabilização de composições de oximetazolina para armazenamento de longo prazo. a presente revelação também é direcionada a composições que compreendem oximetazolina e métodos de tratamento de vários distúrbios oculares relacionados a pálpebras caídas, como ptose, em um sujeito que compreende a administração ao sujeito de composições que compreendem oximetazolina.
BR112021022404A 2019-05-06 2020-05-05 Composições de oximetazolina e métodos para tratamento de distúrbios oculares BR112021022404A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962844069P 2019-05-06 2019-05-06
US201962843819P 2019-05-06 2019-05-06
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
PCT/US2020/031425 WO2020227260A1 (en) 2019-05-06 2020-05-05 Oxymetazoline compositions and methods for treating ocular disorders

Publications (1)

Publication Number Publication Date
BR112021022404A2 true BR112021022404A2 (pt) 2022-01-18

Family

ID=72750169

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022404A BR112021022404A2 (pt) 2019-05-06 2020-05-05 Composições de oximetazolina e métodos para tratamento de distúrbios oculares

Country Status (17)

Country Link
US (11) US10799481B1 (pt)
EP (1) EP3965737A1 (pt)
JP (2) JP7141420B2 (pt)
KR (3) KR102410503B1 (pt)
CN (2) CN117045596A (pt)
AU (1) AU2020268329A1 (pt)
BR (1) BR112021022404A2 (pt)
CA (1) CA3139443A1 (pt)
CL (1) CL2021002918A1 (pt)
CO (1) CO2021015265A2 (pt)
IL (1) IL287831A (pt)
MA (1) MA55895A (pt)
MX (1) MX2021013516A (pt)
PE (1) PE20220384A1 (pt)
SG (1) SG11202112272TA (pt)
WO (1) WO2020227260A1 (pt)
ZA (1) ZA202108950B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US20240156786A1 (en) 2021-03-03 2024-05-16 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP5275214B2 (ja) 2006-03-17 2013-08-28 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 酸化に不安定な成分を含む眼科用安定組成物
JP2009535342A (ja) 2006-04-26 2009-10-01 アーシエックス， インコーポレイテッド 眼瞼腫脹の予防および処置のための組成物
US8466203B2 (en) * 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
AU2008343045A1 (en) * 2007-12-21 2009-07-09 Msd Consumer Care, Inc. Enhancing photostabilization of oxymetazoline
DK2262506T3 (da) * 2008-03-11 2014-06-10 Alcon Res Ltd Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion
EP2437602A4 (en) * 2009-06-05 2014-02-19 Aciex Therapeutics Inc OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
RU2013117209A (ru) * 2010-11-08 2014-10-27 Хилор Лтд. Буферные глазные композиции и способы их применения
ES2618907T3 (es) 2010-12-03 2017-06-22 Allergan, Inc. Composiciones farmacéuticas en crema que comprenden oximetazolina
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2013177594A2 (en) 2012-05-25 2013-11-28 Xlear, Inc. Xylitol-based anti-mucosal compositions and related methods and compositions
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN110505800B (zh) 2013-09-18 2022-02-11 迈康尼股份公司 对smt系统操作员提供信息的方法、系统和设备
ES2796871T3 (es) 2014-06-11 2020-11-30 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
AU2017211793B2 (en) 2016-01-26 2022-11-24 Levation Pharma Ltd. Compositions and uses of alpha-adrenergic agents
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant

Also Published As

Publication number Publication date
US20210386711A1 (en) 2021-12-16
US11541036B2 (en) 2023-01-03
KR102663319B1 (ko) 2024-05-03
CN117045596A (zh) 2023-11-14
CA3139443A1 (en) 2020-11-12
US11311515B2 (en) 2022-04-26
KR20220084264A (ko) 2022-06-21
US20210023222A1 (en) 2021-01-28
JP2020183373A (ja) 2020-11-12
PE20220384A1 (es) 2022-03-18
US20200353083A1 (en) 2020-11-12
US11701343B2 (en) 2023-07-18
SG11202112272TA (en) 2021-12-30
CN111888326A (zh) 2020-11-06
MX2021013516A (es) 2022-01-24
US20230355587A1 (en) 2023-11-09
EP3965737A1 (en) 2022-03-16
JP7141420B2 (ja) 2022-09-22
US10799481B1 (en) 2020-10-13
KR20240060580A (ko) 2024-05-08
WO2020227260A1 (en) 2020-11-12
US20210015795A1 (en) 2021-01-21
US20240033250A1 (en) 2024-02-01
US10814001B1 (en) 2020-10-27
KR20200128629A (ko) 2020-11-16
CO2021015265A2 (es) 2022-02-28
IL287831A (en) 2022-01-01
JP2021191802A (ja) 2021-12-16
US10940138B2 (en) 2021-03-09
ZA202108950B (en) 2023-10-25
AU2020268329A1 (en) 2022-01-06
CL2021002918A1 (es) 2022-08-19
US11103482B2 (en) 2021-08-31
MA55895A (fr) 2022-03-16
US20220257566A1 (en) 2022-08-18
CN111888326B (zh) 2023-07-21
US20220273621A1 (en) 2022-09-01
US20210137889A1 (en) 2021-05-13
US10898573B1 (en) 2021-01-26
US11324722B2 (en) 2022-05-10
KR102410503B1 (ko) 2022-06-17
US20210212992A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
BR112021022404A2 (pt) Composições de oximetazolina e métodos para tratamento de distúrbios oculares
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CL2017001113A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
BR112019009132A2 (pt) composições antimicrobianas sinergísticas
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112020016929A8 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
WO2018143552A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
BR112017004903A2 (pt) composições para fibras de queratina
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
WO2014165713A3 (en) Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
CO2018007236A2 (es) Reguladores cftr y métodos de uso
ECSP21040508A (es) Moduladores de la expresión de foxp3
BR112017009237A2 (pt) composições de éster de forbol e métodos para tratar ou reduzir a duração de citopenia
CO2020003134A2 (es) Moduladores de la expresión de enac
BR112018067453A2 (pt) combinações de glicoalcaloide e vários usos da mesma
MX2015012716A (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.
MX2018000538A (es) Composicion antimicrobiana.
BR112015020182A2 (pt) uso cosmético de queuina ou de um precursor ou um derivado dessa como ingrediente ativo, uso de queuina ou um precursor ou um derivado dessa como ingrediente ativo, composição cosmética e processo de tratamento cosmético para prevenir e/ou tratar sinais de envelhecimento da pele e/ou anexos cutâneos
BR112018006474A2 (pt) nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo